Anterior Spinal Artery Syndrome

1. Disease Information

1.1 What is the disease?

ASAS is a clinical syndrome reflecting ischemic injury in the vascular territory of the anterior spinal artery, usually due to spinal cord infarction. Reviews and case reports consistently frame ASAS as ischemia/obstruction of ASA supply to the anterior two‑thirds of the spinal cord; the tract-level anatomy explains the characteristic dissociation of modalities (motor and pain/temperature more affected than dorsal column modalities). (althobaiti2024anteriorspinalartery pages 1-3, zedde2025spinalcordinfarction pages 2-4)

Direct abstract-supported definition (example, 2023 case literature): Waack et al. state: “Anterior cord syndrome (ACS) occurs as a result of ischemia in the territory of the anterior spinal artery (ASA),” and describe the typical presentation and tract correlates. https://doi.org/10.7759/cureus.40391 (published Jun 2023). (islam2021anteriorspinalartery pages 7-9)

1.2 Key identifiers (OMIM/Orphanet/ICD/MeSH/MONDO)

• MONDO / Orphanet / OMIM: In the retrieved primary literature set, formal MONDO/Orphanet/OMIM IDs were not provided, and ASAS is generally treated as a syndrome/phenotype of vascular spinal cord infarction rather than a monogenic disorder. (althobaiti2024anteriorspinalartery pages 1-3, zedde2025spinalcordinfarction pages 2-4)
• ICD coding: The retrieved corpus did not include a definitive ICD-10/ICD-11 code mapping for “anterior spinal artery syndrome” specifically; contemporary epidemiologic work tends to code at the level of “spinal cord infarction/ischemia” or related stroke/myelopathy categories rather than syndrome-specific labels. (althobaiti2024anteriorspinalartery pages 1-3)
• MeSH: The tool-retrieved content did not provide a direct MeSH descriptor ID for “anterior spinal artery syndrome.” (sliwa1992ischemicmyelopathya pages 1-2)

Knowledge-base note: For a practical knowledge base, ASAS is often represented under broader entities such as “spinal cord infarction,” with ASAS as a clinical presentation subtype. (zedde2025spinalcordinfarction pages 2-4, althobaiti2024anteriorspinalartery pages 1-3)

1.3 Common synonyms and alternative names

Synonyms used in recent literature include: * Anterior cord syndrome (explicitly: “ASAS, alternatively termed anterior cord syndrome”) (althobaiti2024anteriorspinalartery pages 6-7) * Anterior spinal cord infarction and spinal stroke as closely related clinical terms used for the same vascular entity/presentation (althobaiti2024anteriorspinalartery pages 1-3) * Related terms used in search strategies and case literature include spinal cord infarct, spinal cord ischemia, and ASA occlusion/dissection/compression language. (islam2021anteriorspinalartery pages 4-7)

1.4 Evidence source types

The ASAS evidence base is largely: * Aggregated disease-level resources: narrative reviews and systematic reviews of spinal cord infarction/ischemia and aortic surgery complications (batsou2023spinalcordischemia pages 3-3, zedde2025spinalcordinfarction pages 2-4, torre2024enhancingneuroprotectionin pages 8-10) * Human clinical observational cohorts/series (e.g., cohort distributions of SCI subtypes; post-aortic repair prevention protocols) (nagoshi2025imagingcharacteristicsclinical pages 5-8, rosvall2024adedicatedpreventive pages 1-2) * Case reports (helpful for rare iatrogenic triggers and mimics) (althobaiti2024anteriorspinalartery pages 1-3)

2. Etiology

2.1 Disease causal factors (mechanistic)

Causation is typically vascular (arterial occlusion, embolism, or hypoperfusion), leading to ischemic necrosis of the anterior spinal cord (gray matter and adjacent white matter). (zedde2025spinalcordinfarction pages 2-4, batsou2023spinalcordischemia pages 3-3)

2.2 Risk factors (human clinical)

Commonly reported etiologies/risk contexts include: * Aortic disease and aortic procedures (open thoracoabdominal aortic surgery; endovascular repair/EVAR/TEVAR) (zedde2025spinalcordinfarction pages 2-4, rosvall2024adedicatedpreventive pages 1-2) * Systemic hypotension / low-flow states (perioperative or spontaneous) (batsou2023spinalcordischemia pages 3-3, althobaiti2024anteriorspinalartery pages 6-7) * Embolic causes (cardiac embolism; fibrocartilaginous embolism in some contexts) (althobaiti2024anteriorspinalartery pages 6-7, zedde2025spinalcordinfarction pages 2-4) * Vertebral artery dissection/occlusion and posterior circulation procedures causing cervical SCI via hypoperfusion/occlusion (as a general SCI mechanism, relevant to ASA territory) (althobaiti2024anteriorspinalartery pages 6-7) * Neuraxial anesthesia/epidural procedures as iatrogenic contributors in cohort data (nagoshi2025imagingcharacteristicsclinical pages 5-8)

Quantitative vascular risk factor burden: One review summarized that “one or more vascular risk factors” were present in 76% of patients in one study, pooled “at least 1 vascular risk factor” in 81%, and “at least 3” in 45.5%. (batsou2023spinalcordischemia pages 1-2)

Procedure-associated burden: In a 19-patient Japanese cohort (2012–2022), 57.9% of SCI cases were iatrogenic (post-cardiac surgery and epidural anesthesia). (nagoshi2025imagingcharacteristicsclinical pages 5-8)

2.3 Protective factors

Specific protective genetic or environmental factors for ASAS are not well-established in the retrieved literature. In the aortic-surgery context, “protective” measures are largely procedural/perfusion optimization strategies (see Prevention/Treatment sections). (rosvall2024adedicatedpreventive pages 1-2, sufali2024resultsofa pages 1-3)

2.4 Gene–environment interactions

No robust gene–environment interaction framework specific to ASAS was identified in the retrieved papers; however, vascular risk factors (smoking, hypertension, dyslipidemia, diabetes) interact with major environmental/iatrogenic triggers (aortic interventions, hypotension) to influence risk. (zedde2025spinalcordinfarction pages 2-4, althobaiti2024anteriorspinalartery pages 6-7)

3. Phenotypes

3.1 Core phenotypes and suggested HPO terms

Typical clinical features (with suggested HPO mappings): * Acute paraparesis/paraplegia → Paraplegia (HP:0003401), Paraparesis (HP:0001258) * Acute quadriparesis (cervical lesions) → Quadriparesis (HP:0000749) * Loss of pain and temperature sensation → Impaired pain sensation (HP:0007025), Abnormality of temperature sensation (HP:0004370) * Relative sparing of vibration/proprioception (clinical dissociation; often described qualitatively) → consider annotating Normal proprioception (not standard HPO phenotype; document as “dorsal column sparing” clinical feature) * Autonomic dysfunction: urinary retention/incontinence → Urinary retention (HP:0000016) / Urinary incontinence (HP:0000020); bowel dysfunction → Constipation (HP:0002019) or Fecal incontinence (HP:0002607) * Acute back/neck pain → Back pain (HP:0003418), Neck pain (HP:0000467)

These features are repeatedly emphasized in contemporary case literature describing sudden pain and bilateral paralysis with pain/temperature loss and dorsal column sparing, plus autonomic symptoms. (althobaiti2024anteriorspinalartery pages 1-3, islam2021anteriorspinalartery pages 7-9)

3.2 Phenotype characteristics (onset, progression, frequency)

• Temporal pattern: Rapid progression to severe deficit is typical; diagnostic reviews emphasize time to nadir <12 h as a strong clinical predictor for spinal cord infarction diagnosis. (zedde2025spinalcordinfarction pages 2-4)
• Quantitative time-to-nadir distribution (meta-analysis): <6 h 56.1%, 6–12 h 30.7%, 12–72 h 5.4%, >72 h 7.8%. (batsou2023spinalcordischemia pages 3-3)
• Frequency among SCI: In one 19-case cohort, 12/19 presented with ASA syndrome. (nagoshi2025imagingcharacteristicsclinical pages 5-8)

3.3 Quality of life impact

ASAS frequently causes persistent gait impairment and autonomic dysfunction requiring prolonged rehabilitation and long-term support; functional outcomes often reflect initial severity. (batsou2023spinalcordischemia pages 3-3, nagoshi2025imagingcharacteristicsclinical pages 5-8)

4. Genetic / Molecular Information

4.1 Causal genes

ASAS is not typically a monogenic disorder; it is a vascular syndrome. No causal gene list for ASAS exists in the retrieved primary sources. (zedde2025spinalcordinfarction pages 2-4, althobaiti2024anteriorspinalartery pages 1-3)

4.2 Pathogenic variants / modifier genes

Specific inherited thrombophilias are occasionally reported in spinal cord ischemia case literature (outside the retrieved ASAS-focused core set), but within the evidence assembled here, thrombophilia and coagulopathy are treated as risk contexts rather than defining genetic causes. (althobaiti2024anteriorspinalartery pages 6-7)

4.3 Molecular pathways (inferred, not disease-specific omics)

Although ASAS lacks disease-specific omics studies in the retrieved set, ischemia-reperfusion biology implies involvement of: * excitotoxicity, oxidative stress, neuroinflammation, endothelial dysfunction, and microvascular failure. Aortic cross-clamp model review notes predominant gray matter (neuronal) injury and variable subsequent white matter injury, supporting selective anterior horn vulnerability. (awad2021histologicalfindingsafter pages 13-14)

5. Environmental Information

5.1 Environmental and lifestyle risk factors

The main “environmental” contributors are vascular risk behaviors and comorbidities (e.g., smoking, hypertension, dyslipidemia), plus iatrogenic exposures (aortic procedures, neuraxial anesthesia). A review reports smoking prevalence around 30%, hypertension 40%, dyslipidemia 29%, diabetes 16% among SCI cases in one synthesis. (zedde2025spinalcordinfarction pages 2-4)

5.2 Infectious agents

No specific infectious causal agent is established for ASAS in the retrieved evidence set. (zedde2025spinalcordinfarction pages 2-4)

6. Mechanism / Pathophysiology

6.1 Causal chain (clinical mechanism)

1. Trigger: ASA occlusion, embolus, hypoperfusion (hypotension), or peri-aortic procedure collateral disruption. (batsou2023spinalcordischemia pages 3-3, zedde2025spinalcordinfarction pages 2-4)
2. Primary lesion: ischemia of ASA territory (anterior two‑thirds), especially metabolically vulnerable gray matter/anterior horns. (zedde2025spinalcordinfarction pages 2-4, awad2021histologicalfindingsafter pages 13-14)
3. Clinical manifestation: motor deficits (corticospinal/anterior horn), pain/temperature loss (spinothalamic), autonomic dysfunction (lateral horn/intermediolateral cell columns), with dorsal column sparing. (zedde2025spinalcordinfarction pages 2-4, althobaiti2024anteriorspinalartery pages 1-3)

6.2 Tissue injury mechanisms

Preclinical aortic cross-clamp models show a conserved pattern: injury is “predominantly in the grey matter,” with anterior gray matter often worse, and white matter injury emerging later. (awad2021histologicalfindingsafter pages 13-14)

6.3 Suggested ontology terms

• GO biological process: ischemic process; response to hypoxia; neuron death; inflammatory response; angiogenesis.
• CL cell types: spinal motor neuron; astrocyte; microglial cell; vascular endothelial cell.
• UBERON anatomy: spinal cord; anterior horn of spinal cord; thoracic spinal cord; conus medullaris.

(These are mechanistically motivated; ontology IDs were not provided in the retrieved papers.)

7. Anatomical Structures Affected

7.1 Organ/system level

Primary: spinal cord (central nervous system), particularly anterior horn and anterior/lateral white matter supplied by ASA. (zedde2025spinalcordinfarction pages 2-4)

7.2 Localization

Thoracolumbar involvement is common in SCI; one review notes ~65% thoracolumbar region involvement and that cervical infarctions may present more severely with autonomic dysfunction/upper extremity impairment. (zedde2025spinalcordinfarction pages 2-4)

8. Temporal Development

8.1 Onset

Usually acute/hyperacute. Diagnostic reviews emphasize severe deficits developing rapidly (within <12 h) as a core discriminant from inflammatory etiologies. (zedde2025spinalcordinfarction pages 2-4, batsou2023spinalcordischemia pages 3-3)

8.2 Progression

Symptoms often peak quickly (majority by 72 h), but imaging can lag: DWI may detect early lesions before T2 changes in some patients. In a cohort, DWI within 2 days detected lesions in 62.5% (5/8), and a representative case showed DWI positivity on day 2 and T2 changes by day 6. (nagoshi2025imagingcharacteristicsclinical pages 5-8)

9. Inheritance and Population

9.1 Epidemiology

Robust epidemiology is limited; a 2025 review states incidence is “not well documented” and likely underestimated. (zedde2025spinalcordinfarction pages 2-4)

Quantitative estimates (spinal cord infarction, not ASAS-specific): * SCI ~1–2% of all strokes and 5–8% of acute myelopathies. (zedde2025spinalcordinfarction pages 2-4) * Population incidence reported as 3.1/100,000 person-years (95% CI 1.6–7.2) in one study cited in review. (zedde2025spinalcordinfarction pages 2-4)

9.2 Demographics

Vascular risk factors are common but not universal; one review cites 28% with no reported vascular risk factors. (zedde2025spinalcordinfarction pages 2-4)

10. Diagnostics

10.1 Clinical criteria and diagnostic approach

A contemporary review summarizes proposed diagnostic criteria for spinal cord infarction that are directly applicable to ASAS: 1) Rapid development of severe deficits within 12 h; 2) MRI supportive of infarction and excluding compression; 3) Non-inflammatory CSF. Patients may be categorized as definite/probable/possible SCI. (batsou2023spinalcordischemia pages 3-3)

Another contemporary review stresses that “lack of cord compression on MRI is the only mandatory feature” in proposed criteria, highlighting the need to exclude compressive myelopathy. (zedde2025spinalcordinfarction pages 2-4)

10.2 Imaging

MRI findings supporting ASAS include: * axial “owl’s eye” / “snake-eye” anterior horn hyperintensity, * sagittal “pencil-like” anterior T2 hyperintensity, * diffusion restriction (DWI), and often absence of early enhancement. (batsou2023spinalcordischemia pages 1-2, althobaiti2024anteriorspinalartery pages 1-3)

Image evidence: A 2024 case report figure demonstrates ASA territory infarction with “owl’s eye/snake-eye” appearance on T2/DWI. (ferreira2024anteriorspinalcord media 08b84382)

11. Outcome / Prognosis

11.1 Functional outcomes

A review summarizes that favorable functional outcome ~40–50%, and “about half of initially non-ambulatory survivors regained walking.” (batsou2023spinalcordischemia pages 3-3)

In the 19-patient cohort, ASAS predicted poorer ambulatory outcomes: 11/13 (84.6%) of the poor prognosis group had ASA syndrome, whereas Brown–Séquard presentations were associated with better gait outcomes. (nagoshi2025imagingcharacteristicsclinical pages 5-8)

11.2 Prognostic factors

Worse outcomes associate with more severe initial impairment (ASIA A/B), sensory level, and longitudinally extensive MRI lesions. (batsou2023spinalcordischemia pages 3-3)

12. Treatment

12.1 Acute and subacute medical management (evidence-limited)

There is no high-quality ASAS-specific randomized trial base; management is typically extrapolated from vascular neurology and the precipitating cause.

A 2023 review summarized treatment frequencies across series: antiplatelet agents 68%, anticoagulation 8%, blood pressure augmentation 6%, lumbar drain 6%; it also notes limited evidence and uncertainty, particularly for CSF drainage in spontaneous SCI. (batsou2023spinalcordischemia pages 3-3)

12.2 Aortic-repair associated prevention and management (2023–2024 real-world implementation)

The most protocolized “real‑world implementation” literature is peri‑aortic repair spinal cord protection.

Protocol example (Frontiers in Cardiovascular Medicine, Aug 2024): Rosvall et al. reported a prevention protocol for complex EVAR with targets MAP >80 mmHg, Hb >110 g/L, early lower limb reperfusion, and hourly neurologic checks for 36–72 h; prophylactic CSFD used selectively. SCI incidence was 1.3% (juxtarenal) and 6.0% (TAAA); persistent SCI after regression was 0.6% (JRA) and 4.0% (TAAA). https://doi.org/10.3389/fcvm.2024.1440674 (Aug 2024). (rosvall2024adedicatedpreventive pages 1-2)

Protocol example (Vessel Plus, Jan 2024): Sufali et al. reported a multidisciplinary prevention protocol for elective fenestrated/branched repairs with staging in 80%, MAP >80 mmHg, Hb >10 g/dL, routine CSFD, and neuromonitoring. Outcomes: overall SCI 8% (2% transient; 6% permanent), permanent paraplegia 3%, 30‑day mortality 3%, in-hospital mortality 7%, and worse 2‑year survival with SCI (18% vs 69%). https://doi.org/10.20517/2574-1209.2023.139 (Jan 2024). (sufali2024resultsofa pages 1-3)

Expert synthesis (Anesthesia Research, Aug 2024): Torre & Pirri summarize rescue management prioritizing perfusion: increase MAP (cited target >100 mmHg) and transfuse to Hb >10 g/dL, combined with CSFD; they cite neurologic improvement in 57% of delayed deficits and complete resolution in 17% in aggregated reports. https://doi.org/10.3390/anesthres1020010 (Aug 2024). (torre2024enhancingneuroprotectionin pages 10-11, torre2024enhancingneuroprotectionin pages 8-10)

12.3 Suggested MAXO terms (treatment actions)

• Antiplatelet therapy; Anticoagulation therapy; Blood pressure augmentation; Cerebrospinal fluid drainage; Endovascular aortic repair management; Physical rehabilitation therapy; Bladder catheterization/management. (MAXO IDs not provided in retrieved papers; actions are supported as clinical interventions.) (batsou2023spinalcordischemia pages 3-3, rosvall2024adedicatedpreventive pages 1-2)

13. Prevention

Primary prevention is mainly risk reduction for vascular events and prevention of iatrogenic SCI in high-risk procedures.

Aortic procedure prevention (real-world): Staging extensive repairs, maintaining MAP and Hb targets, collateral bed optimization, neurologic monitoring, and selective/routine CSFD reduce persistent injury rates in modern series. (rosvall2024adedicatedpreventive pages 1-2, sufali2024resultsofa pages 1-3)

14. Other Species / Natural Disease

No naturally occurring ASAS “disease entity” in non-human species was identified in the retrieved evidence set; the translational literature primarily uses induced ischemia models. (awad2021histologicalfindingsafter pages 1-2)

15. Model Organisms

ASAS mechanisms (ischemic anterior spinal cord vulnerability) are modeled using aortic cross-clamp or segmental artery ligation paradigms (mimicking open repair or TEVAR) and photochemical/photothrombotic ischemia models.

15.1 TEVAR-like / segmental artery ligation model (mouse; 2023)

Kelani et al. (Anesthesiology, Jan 2023) ligated five pairs of thoracic intercostal arteries to model TEVAR-associated hypoperfusion. * Spinal cord blood flow drop: thoracic spinal cord mean −68.55% (95% CI −80.23 to −56.87). * Day‑1 paralysis severity distribution: 9.4% severe, 37.5% moderate, 53.1% mild. * Severe paralysis mortality: 83% (15/18) vs moderate 33% and mild 24%. The authors state the model yields variable severity and reversibility resembling clinical variability after aortic repair. https://doi.org/10.1097/ALN.0000000000004515 (Jan 2023). (kelani2023mousemodelof pages 1-3)

15.2 Aortic cross-clamp delayed paralysis model (mouse; 2010)

Awad et al. (Anesthesiology, Oct 2010) developed a murine descending aortic cross-clamp model producing delayed paralysis (24–36 h) with >95% survival through 9 weeks under an optimal protocol (7.5 min clamp at 33°C). It produced severe hindlimb paralysis in 70% (19/27) and mild but permanent deficits in the remainder, enabling long-term mechanistic and therapy studies. https://doi.org/10.1097/ALN.0b013e3181ec61ee (Oct 2010). (awad2010amousemodel pages 1-2)

15.3 Simplified spinal cord ischemia model (mouse; 2010)

Wang et al. (J Neurosci Methods, Jun 2010) reported clamp durations of 0–12 min with “approximately 90% blood flow reduction” in lumbar spinal cord during cross-clamping; 10-min injury produced persistent deficits with 28‑day survival 80% (4/5) in an injured group. https://doi.org/10.1016/j.jneumeth.2010.04.003 (Jun 2010). (wang2010developmentofa pages 1-2)

15.4 Histopathology across species (systematic review; 2021)

A systematic review of aortic cross-clamp models concluded injury is predominantly gray matter, with neuronal degeneration in over two‑thirds of cases and anterior gray matter often worse—consistent with anterior horn vulnerability central to ASAS. https://doi.org/10.1093/jnen/nlab084 (Sep 2021). (awad2021histologicalfindingsafter pages 13-14)

Recent developments & latest research emphasis (2023–2024)

Key 2023–2024 advances in this corpus are pragmatic rather than molecular: 1. Refined diagnostic frameworks emphasizing time to nadir, MRI exclusion of compression, and non-inflammatory CSF. (batsou2023spinalcordischemia pages 3-3) 2. More explicit reporting of DWI utility and radiologic lag, including cohort-level estimates and early DWI detection fractions. (nagoshi2025imagingcharacteristicsclinical pages 5-8) 3. Protocolized spinal cord protection bundles for complex EVAR/branched repairs with specific physiologic targets (MAP/Hb), staging, and neurologic monitoring, with measured reductions in persistent SCI and documentation of risk strata (sex, rupture, renal insufficiency, low MAP). (rosvall2024adedicatedpreventive pages 1-2, sufali2024resultsofa pages 1-3) 4. Translational TEVAR-like murine models (2023) enabling mechanistic study of collateral variability and tissue injury patterns that resemble human TEVAR-related spinal cord injury heterogeneity. (kelani2023mousemodelof pages 1-3)

Current applications and real-world implementations

• ICU protocols after complex aortic repair with hourly neurological checks (36–72 h), MAP and hemoglobin targets, early limb reperfusion, and selective CSF drainage are real-world implementations aimed at reducing permanent neurologic injury. (rosvall2024adedicatedpreventive pages 1-2)
• Multidisciplinary prevention pathways integrating vascular surgery, anesthesiology, neuromonitoring, and neuroimaging for early detection and rescue. (sufali2024resultsofa pages 1-3, torre2024enhancingneuroprotectionin pages 10-11)

Expert opinions / analysis (authoritative sources)

Authoritative review analyses emphasize that SCI/ASAS remains underdiagnosed and lacks strong epidemiology; many cases are misdiagnosed as inflammatory myelopathies, and diagnostic pathways are often incomplete. (zedde2025spinalcordinfarction pages 2-4)

Aortic-surgery neuroprotection reviews stress a physiology-based principle: spinal cord perfusion pressure is approximated by MAP minus CSF pressure, motivating CSFD and permissive hypertension/anemia correction as rescue strategies. (torre2024enhancingneuroprotectionin pages 8-10)

Statistics and data highlights

• SCI population incidence: 3.1/100,000 person-years (review-cited estimate). (zedde2025spinalcordinfarction pages 2-4)
• Time to nadir distribution: <6 h 56.1%, 6–12 h 30.7% (meta-analysis). (batsou2023spinalcordischemia pages 3-3)
• ASA syndrome frequency in a cohort: 12/19 cases. (nagoshi2025imagingcharacteristicsclinical pages 5-8)
• Complex EVAR protocol outcomes (Aug 2024): SCI 1.3% (JRA) and 6.0% (TAAA); persistent SCI 0.6% and 4.0% after regression. (rosvall2024adedicatedpreventive pages 1-2)
• F/B‑EVAR protocol outcomes (Jan 2024): overall SCI 8%, permanent paraplegia 3%. (sufali2024resultsofa pages 1-3)

Visual evidence

The following MRI figure demonstrates classic ASA-territory infarction imaging (including the “owl’s eye/snake-eye” sign) supportive of ASAS diagnosis. (ferreira2024anteriorspinalcord media 08b84382)

Synthesis artifact

Table: This table condenses recent and foundational evidence on anterior spinal artery syndrome, including presentation, causes, diagnostics, prognosis, and current treatment/prevention strategies. It is designed as a quick-reference artifact for knowledge base curation and citation mapping.

Limitations of this report (evidence gaps relative to template)

• Formal MONDO/MeSH/Orphanet/ICD identifiers for ASAS were not found in the retrieved full-text excerpts and would require dedicated ontology lookups beyond the current paper set. (althobaiti2024anteriorspinalartery pages 1-3, sliwa1992ischemicmyelopathya pages 1-2)
• High-quality ASAS-specific randomized evidence for antithrombotic selection (antiplatelet vs anticoagulant) is limited; most recommendations are extrapolated from SCI series or the underlying etiology (e.g., aortic repair context). (batsou2023spinalcordischemia pages 3-3)

Primary-source URLs (examples, with publication dates)

• Rosvall L, et al. Front Cardiovasc Med. Aug 2024. “A dedicated preventive protocol sustainably avoids spinal cord ischemia after endovascular aortic repair.” https://doi.org/10.3389/fcvm.2024.1440674 (rosvall2024adedicatedpreventive pages 1-2)
• Sufali G, et al. Vessel Plus. Jan 2024. “Results of a multidisciplinary spinal cord ischemia prevention protocol…” https://doi.org/10.20517/2574-1209.2023.139 (sufali2024resultsofa pages 1-3)
• Torre DE, Pirri C. Anesthesia Research. Aug 2024. “Enhancing Neuroprotection in Cardiac and Aortic Surgeries: A Narrative Review.” https://doi.org/10.3390/anesthres1020010 (torre2024enhancingneuroprotectionin pages 10-11)
• Kelani H, et al. Anesthesiology. Jan 2023. “Mouse Model of Spinal Cord Hypoperfusion…” https://doi.org/10.1097/aln.0000000000004515 (kelani2023mousemodelof pages 1-3)
• Zedde M, et al. J Clin Med. Feb 2025. “Spinal Cord Infarction: Clinical and Neuroradiological Clues…” https://doi.org/10.3390/jcm14041293 (zedde2025spinalcordinfarction pages 2-4)

References

1. (althobaiti2024anteriorspinalartery pages 1-3): Faisal A. Althobaiti, Rayan I. Maghrabi, Naif F Alharbi, Mohammed M Alwadai, Maha K Almatrafi, and Somaya Bajammal. Anterior spinal artery syndrome in a patient with multilevel cervical disc disease: a case report. Cureus, Jul 2024. URL: https://doi.org/10.7759/cureus.64577, doi:10.7759/cureus.64577. This article has 3 citations.

2. (althobaiti2024anteriorspinalartery pages 6-7): Faisal A. Althobaiti, Rayan I. Maghrabi, Naif F Alharbi, Mohammed M Alwadai, Maha K Almatrafi, and Somaya Bajammal. Anterior spinal artery syndrome in a patient with multilevel cervical disc disease: a case report. Cureus, Jul 2024. URL: https://doi.org/10.7759/cureus.64577, doi:10.7759/cureus.64577. This article has 3 citations.

3. (zedde2025spinalcordinfarction pages 2-4): Marialuisa Zedde, Arturo De Falco, Carla Zanferrari, Maria Guarino, Francesca Romana Pezzella, Shalom Haggiag, Gianni Cossu, Rocco Quatrale, Giuseppe Micieli, Massimo Del Sette, and Rosario Pascarella. Spinal cord infarction: clinical and neuroradiological clues of a rare stroke subtype. Journal of Clinical Medicine, 14:1293, Feb 2025. URL: https://doi.org/10.3390/jcm14041293, doi:10.3390/jcm14041293. This article has 16 citations.

4. (batsou2023spinalcordischemia pages 3-3): V Batsou, IS Benetos, and I Vlamis. Spinal cord ischemia: a review of clinical and imaging features, risk factors and long-term prognosis. Unknown journal, 2023.

5. (rosvall2024adedicatedpreventive pages 1-2): Lina Rosvall, Angelos Karelis, Björn Sonesson, and Nuno V. Dias. A dedicated preventive protocol sustainably avoids spinal cord ischemia after endovascular aortic repair. Frontiers in Cardiovascular Medicine, Aug 2024. URL: https://doi.org/10.3389/fcvm.2024.1440674, doi:10.3389/fcvm.2024.1440674. This article has 8 citations and is from a peer-reviewed journal.

6. (sufali2024resultsofa pages 1-3): Gemmi Sufali, Gianluca Faggioli, Enrico Gallitto, Rodolfo Pini, Andrea Vacirca, Chiara Mascoli, and Mauro Gargiulo. Results of a multidisciplinary spinal cord ischemia prevention protocol in elective repair of crawford's extent i-iii thoracoabdominal aneurysm by fenestrated and branched endografts. Vessel Plus, 8:16, Jan 2024. URL: https://doi.org/10.20517/2574-1209.2023.139, doi:10.20517/2574-1209.2023.139. This article has 1 citations.

7. (torre2024enhancingneuroprotectionin pages 10-11): Debora Emanuela Torre and Carmelo Pirri. Enhancing neuroprotection in cardiac and aortic surgeries: a narrative review. Anesthesia Research, 1:91-109, Aug 2024. URL: https://doi.org/10.3390/anesthres1020010, doi:10.3390/anesthres1020010. This article has 3 citations.

8. (islam2021anteriorspinalartery pages 7-9): Asraful Islam, Mohammad D Hossain, Abu Bakar Siddik, Tyfur Rahman, Ashraful Alam, Md Manjurul Islam Shourav, Nahian Afrida, Sajedur Rahman, and Masum Rahman. Anterior spinal artery syndrome due to intervertebral disc herniation: a systematic review. Journal of Spine Research and Surgery, Mar 2021. URL: https://doi.org/10.1101/2021.03.18.21253916, doi:10.1101/2021.03.18.21253916. This article has 1 citations.

9. (sliwa1992ischemicmyelopathya pages 1-2): James A. Sliwa and Ian C. Maclean. Ischemic myelopathy: a review of spinal vasculature and related clinical syndromes. Archives of physical medicine and rehabilitation, 73 4:365-72, Apr 1992. URL: https://doi.org/10.1016/0003-9993(92)90011-k, doi:10.1016/0003-9993(92)90011-k. This article has 150 citations and is from a highest quality peer-reviewed journal.

10. (islam2021anteriorspinalartery pages 4-7): Asraful Islam, Mohammad D Hossain, Abu Bakar Siddik, Tyfur Rahman, Ashraful Alam, Md Manjurul Islam Shourav, Nahian Afrida, Sajedur Rahman, and Masum Rahman. Anterior spinal artery syndrome due to intervertebral disc herniation: a systematic review. Journal of Spine Research and Surgery, Mar 2021. URL: https://doi.org/10.1101/2021.03.18.21253916, doi:10.1101/2021.03.18.21253916. This article has 1 citations.

11. (torre2024enhancingneuroprotectionin pages 8-10): Debora Emanuela Torre and Carmelo Pirri. Enhancing neuroprotection in cardiac and aortic surgeries: a narrative review. Anesthesia Research, 1:91-109, Aug 2024. URL: https://doi.org/10.3390/anesthres1020010, doi:10.3390/anesthres1020010. This article has 3 citations.

12. (nagoshi2025imagingcharacteristicsclinical pages 5-8): Narihito Nagoshi, Yasuhiro Kamata, Toshiki Okubo, Masahiro Ozaki, Satoshi Suzuki, Kazuki Takeda, Takahito Iga, Kentaro Shimizu, Morio Matsumoto, Masaya Nakamura, and Kota Watanabe. Imaging characteristics, clinical presentation, and prognosis of spinal cord infarction. Jun 2025. URL: https://doi.org/10.21203/rs.3.rs-6730915/v1, doi:10.21203/rs.3.rs-6730915/v1.

13. (batsou2023spinalcordischemia pages 1-2): V Batsou, IS Benetos, and I Vlamis. Spinal cord ischemia: a review of clinical and imaging features, risk factors and long-term prognosis. Unknown journal, 2023.

14. (awad2021histologicalfindingsafter pages 13-14): Hamdy Awad, Alexander Efanov, Jayanth Rajan, Andrew Denney, Bradley Gigax, Peter Kobalka, Hesham Kelani, D Michele Basso, John Bozinovski, and Esmerina Tili. Histological findings after aortic cross-clamping in preclinical animal models. Journal of neuropathology and experimental neurology, 80:895-911, Sep 2021. URL: https://doi.org/10.1093/jnen/nlab084, doi:10.1093/jnen/nlab084. This article has 12 citations and is from a peer-reviewed journal.

15. (ferreira2024anteriorspinalcord media 08b84382): Sílvia Ferreira, Angelo Fonseca, Filipe Correia, Joana Cunha, and Mariana Taveira. Anterior spinal cord infarction: a rare diagnosis with an uncommon presentation. Cureus, Jul 2024. URL: https://doi.org/10.7759/cureus.64083, doi:10.7759/cureus.64083. This article has 3 citations.

16. (awad2021histologicalfindingsafter pages 1-2): Hamdy Awad, Alexander Efanov, Jayanth Rajan, Andrew Denney, Bradley Gigax, Peter Kobalka, Hesham Kelani, D Michele Basso, John Bozinovski, and Esmerina Tili. Histological findings after aortic cross-clamping in preclinical animal models. Journal of neuropathology and experimental neurology, 80:895-911, Sep 2021. URL: https://doi.org/10.1093/jnen/nlab084, doi:10.1093/jnen/nlab084. This article has 12 citations and is from a peer-reviewed journal.

17. (kelani2023mousemodelof pages 1-3): Hesham Kelani, Kara Corps, Sarah Mikula, Lesley C. Fisher, Mahmoud T. Shalaan, Sarah Sturgill, Mark T. Ziolo, Mahmoud Abdel-Rasoul, D. Michele Basso, and Hamdy Awad. Mouse model of spinal cord hypoperfusion with immediate paralysis caused by endovascular repair of thoracic aortic aneurysm. Anesthesiology, 138:403-419, Jan 2023. URL: https://doi.org/10.1097/aln.0000000000004515, doi:10.1097/aln.0000000000004515. This article has 2 citations and is from a domain leading peer-reviewed journal.

18. (awad2010amousemodel pages 1-2): Hamdy Awad, Daniel P. Ankeny, Zhen Guan, Ping Wei, Dana M. McTigue, and Phillip G. Popovich. A mouse model of ischemic spinal cord injury with delayed paralysis caused by aortic cross-clamping. Anesthesiology, 113:880-891, Oct 2010. URL: https://doi.org/10.1097/aln.0b013e3181ec61ee, doi:10.1097/aln.0b013e3181ec61ee. This article has 72 citations and is from a domain leading peer-reviewed journal.

19. (wang2010developmentofa pages 1-2): Zhengfeng Wang, Wei Yang, Gavin W. Britz, Frederick W. Lombard, David S. Warner, and Huaxin Sheng. Development of a simplified spinal cord ischemia model in mice. Journal of Neuroscience Methods, 189:246-251, Jun 2010. URL: https://doi.org/10.1016/j.jneumeth.2010.04.003, doi:10.1016/j.jneumeth.2010.04.003. This article has 18 citations and is from a peer-reviewed journal.

20. (sufali2024resultsofa pages 3-5): Gemmi Sufali, Gianluca Faggioli, Enrico Gallitto, Rodolfo Pini, Andrea Vacirca, Chiara Mascoli, and Mauro Gargiulo. Results of a multidisciplinary spinal cord ischemia prevention protocol in elective repair of crawford's extent i-iii thoracoabdominal aneurysm by fenestrated and branched endografts. Vessel Plus, 8:16, Jan 2024. URL: https://doi.org/10.20517/2574-1209.2023.139, doi:10.20517/2574-1209.2023.139. This article has 1 citations.

21. (krzyzaniak2024complicationsofcerebrospinal pages 1-2): MD Halli Krzyzaniak, BN Martina Vergouwen, MD Darren Van Essen, MD Curtis Nixon, MD R. Scott McClure, MD Nadeem Jadavji, M. M. Randy D. Moore, and MD Kenton Rommens. Complications of cerebrospinal fluid drainage in thoracoabdominal aortic procedures. Canadian Journal of Surgery, 67:E389-E396, Dec 2024. URL: https://doi.org/10.1503/cjs.003624, doi:10.1503/cjs.003624. This article has 1 citations and is from a peer-reviewed journal.

22. (rosvall2024adedicatedpreventive pages 2-3): Lina Rosvall, Angelos Karelis, Björn Sonesson, and Nuno V. Dias. A dedicated preventive protocol sustainably avoids spinal cord ischemia after endovascular aortic repair. Frontiers in Cardiovascular Medicine, Aug 2024. URL: https://doi.org/10.3389/fcvm.2024.1440674, doi:10.3389/fcvm.2024.1440674. This article has 8 citations and is from a peer-reviewed journal.

1. Disease Information

Overview

Anterior Spinal Artery Syndrome (ASAS) is an ischemic myelopathy resulting from occlusion or hypoperfusion of the anterior spinal artery or its feeding radiculomedullary arteries. The anterior spinal artery supplies the ventral two-thirds of the spinal cord, including the corticospinal tracts, spinothalamic tracts, and anterior horn motor neurons, while sparing the dorsal columns. This vascular territory explains the hallmark dissociated sensory loss: pain and temperature sensation are lost while proprioception and vibration are preserved. ASAS is a medical emergency with significant morbidity and mortality. The syndrome is most commonly associated with aortic pathology but can also result from embolic events, vasculitis, and other vascular causes.

Key Identifiers

Synonyms and Alternative Names

• Anterior spinal artery syndrome
• Anterior spinal cord syndrome
• Anterior cord syndrome
• Beck syndrome
• Anterior spinal artery occlusion syndrome
• Ventral spinal cord syndrome
• Spinal cord anterior artery syndrome

Data Sources

This characterization is derived from aggregated disease-level resources including published clinical series, case reports, review articles, and biomedical ontology databases. No individual patient-level EHR data were used. A total of 107 papers were reviewed for this report.

2. Etiology

Disease Causal Factors

ASAS is fundamentally a vascular/ischemic disorder caused by interruption of blood flow through the anterior spinal artery or its feeder vessels. The primary causal mechanism is arterial occlusion (thrombotic, embolic, or hemodynamic) leading to ischemic infarction of the anterior two-thirds of the spinal cord.

Etiological breakdown from major clinical series:

In a landmark 19.8-year cohort study of 55 consecutive spinal cord ischemia patients: "Aetiologies of infarcts were arteriosclerosis of the aorta and vertebral arteries (23.6%), aortic surgery or interventional aneurysm repair (11%) and aortic and vertebral artery dissection (11%), and in 23.6%, aetiology remained unclear" (PMID: 25398656).

In a separate series of 36 spinal cord infarction patients: "the commonest group being spinal cord ischemia due to idiopathic causes (36.1%). Following these, there were cases associated with aortic surgery (25%), systemic arteriosclerosis (19.4%) and acute deficit of perfusion (11.1%)" (PMID: 11641795).

Specific etiological categories include:

1. Aortic pathology (most common identifiable cause): Aortic dissection (Type A and B), aortic aneurysm with mural thrombus (PMID: 29506472), thoracic endovascular aortic repair (TEVAR), open thoracoabdominal aortic surgery (PMID: 12483181), intra-aortic balloon pump complications (PMID: 27736197)

2. Fibrocartilaginous embolism (rare, younger patients): "Fibrocartilaginous nucleus pulposus components herniation and embolism rarely causes acute ischaemic events involving the spinal cord. Few reports have suggested this as a mechanism leading to anterior spinal artery syndrome" (PMID: 36114979)

3. Vasculitis: Behçet's disease (PMID: 22892002, PMID: 22193225), systemic lupus erythematosus (PMID: 29900713)

4. Iatrogenic: Spinal surgery complications (PMID: 32502625), spinal anesthesia (PMID: 27184089)

5. Hypercoagulable states: COVID-19-associated coagulopathy (PMID: 38365009)

6. Vertebral artery occlusion/dissection: (PMID: 41137336)

7. Hemodynamic: Systemic hypotension, cardiac arrest (PMID: 41690059)

Risk Factors

Cardiovascular risk factors: Smoking, hypertension, diabetes mellitus, and hypercholesterolemia are identified as the major risk factors (PMID: 22962400). Mean age at presentation is approximately 59.3 years (PMID: 11641795), with male predominance (66.6% in some series — PMID: 38365009).

Surgical/procedural risk factors: Prolonged aortic cross-clamp time (PMID: 12483181), coverage of the left subclavian artery during TEVAR (PMID: 29788799), hyperkyphosis correction, combined anterior-posterior spinal procedures (PMID: 32871559).

A predictive risk score (0–6 points) for SCI after open TAAA repair achieved AUC 0.919, based on: TAAA extent II, BMI ≥30, smoking history, preoperative diuretic use, age >70, and chronic kidney disease (PMID: 41205836).

Anatomic risk factors: Variant spinal cord arterial supply with limited collateral networks, anomalously low origin of the artery of Adamkiewicz (PMID: 12483181).

Genetic risk factors: No specific genetic variants are causal for ASAS. However, genetic conditions affecting vascular integrity (Marfan syndrome — FBN1; Loeys-Dietz syndrome — TGFBR1/TGFBR2; vascular Ehlers-Danlos — COL3A1) predispose to aortic pathology which can secondarily cause ASAS.

Protective Factors

• Robust collateral arterial networks (complete Circle of Willis, well-developed segmental medullary arteries)
• Multiple radiculomedullary arteries (present in ~32% of individuals — PMID: 36152330)
• Dominant anterior thoracic artery present in 94% of individuals (PMID: 36581455)
• Cardiovascular risk factor modification (BP control, lipid management, smoking cessation)
• Perioperative spinal cord protection protocols (CSF drainage, staged repair, MISACE — PMID: 41418893)

Gene-Environment Interactions

No specific gene-environment interactions have been characterized for ASAS. The disease is predominantly acquired through vascular mechanisms rather than genetic predisposition.

3. Phenotypes

Core Clinical Presentation

ASAS presents with a characteristic triad. As described in a comprehensive review: "Acute occlusion of the anterior spinal artery and subsequent spinal ischemic infarction leads to anterior spinal artery syndrome characterized by back pain and bilateral flaccid paresis with loss of protopathic sensibility" (PMID: 37164315).

In a clinical series of 17 patients: "Clinical presentation included dissociative anesthesia, weakness of limbs, back or neck pain, and autonomic symptoms with symptom onset to peak time ranging from few minutes to 48 hours" (PMID: 30093205).

The syndrome accounts for 49% of spinal cord ischemia: "49% of patients suffered from centromedullar syndrome caused by anterior spinal artery ischemia" (PMID: 25398656).

Phenotype Catalog

Pediatric Phenotype

In children/adolescents, fibrocartilaginous embolism is the most characteristic cause. Mean age at presentation is 13.2 years. All 7 children in one series had bladder dysfunction requiring catheterization, and neurogenic bladder persisted in 6/7 at last follow-up (PMID: 28578817).

Quality of Life Impact

ASAS has a devastating impact on quality of life. At discharge, 57.1% of patients are wheelchair users, 25% are ambulatory with technical aids, and only 17.9% achieve full ambulation (PMID: 11641795). Neurogenic bladder dysfunction persists in the majority of patients long-term.

4. Genetic/Molecular Information

Causal Genes

ASAS is not a Mendelian genetic disorder. No causal genes, pathogenic variants, or chromosomal abnormalities are directly responsible. It is an acquired vascular condition.

Relevant Genetic Context

Genes involved in predisposing conditions include:

Molecular Pathways in Ischemia-Reperfusion Injury

The molecular cascades activated during spinal cord ischemia are well-characterized from preclinical research:

• PI3K/Akt/GSK-3β pathway: Neuroprotective signaling; astaxanthin activation improves outcomes (PMID: 32703256)
• Nrf2/HO-1 pathway: Antioxidant defense; targeted by hydrogen therapy and melatonin (PMID: 41579273, PMID: 40684392)
• NF-κB signaling: Pro-inflammatory cascade activation
• NLRP3 inflammasome: Drives pyroptosis and neuroinflammation
• HMGB1 signaling: Anti-HMGB1 antibody therapy improved neurological outcomes in a rabbit SCIRI model: "Treatment with anti-HMGB1 mAb significantly improved neurological outcomes, reduced the extent of spinal cord infarction, preserved motor neuron viability, and decreased the presence of activated microglia and infiltrating neutrophils" (PMID: 40943562)
• CaMKII pathway: Inhibition with tatCN19o showed neuroprotective effects in mouse spinal cord ischemia model (PMID: 40885467)

Epigenetic and Chromosomal Information

No disease-specific epigenetic changes or chromosomal abnormalities have been described for ASAS.

5. Environmental Information

Environmental Factors

• Iatrogenic: Aortic surgery (open repair, TEVAR), spinal surgery, spinal anesthesia, intra-aortic balloon pump use — the most significant modifiable risk factors
• Trauma: Cervical facet dislocation (VA occlusion in 24% — PMID: 39043672), minor physical trauma triggering fibrocartilaginous embolism
• Atherosclerotic burden: Smoking, hypertension, hyperlipidemia, diabetes

Lifestyle Factors

• Smoking: Major vascular risk factor (PMID: 22962400)
• Intense physical activity: Paradoxically, a trigger for fibrocartilaginous embolism in young patients; the most common trigger event in pediatric cases was intense exercise or sports (PMID: 31201068)
• Sedentary lifestyle/metabolic syndrome: Contributes to vascular risk

Infectious Agents

SARS-CoV-2: COVID-19-associated coagulopathy linked to spinal cord ischemia. In a systematic review: "Sixty-six percent of the patients had severe COVID-19. Five data sets reported preexisting coagulopathy. ... Anterior spinal artery lesions were the most prevalent ischemic pattern" (PMID: 38365009).

6. Mechanism / Pathophysiology

The Causal Chain

INITIAL TRIGGER
    │
    ├── Aortic pathology (atherosclerosis, dissection, surgery)
    ├── Embolism (cardiac, fibrocartilaginous, atheromatous)
    ├── Hypoperfusion (hypotension, cardiac arrest)
    └── Vessel compression/occlusion
    │
    ▼
VASCULAR OCCLUSION/HYPOPERFUSION
    │
    ├── Anterior spinal artery occlusion
    ├── Radiculomedullary artery occlusion (e.g., artery of Adamkiewicz)
    └── Sulcal/sulcocommissural artery occlusion
    │
    ▼
SPINAL CORD ISCHEMIA (ventral 2/3)
    │
    ├── Energy failure (ATP depletion)
    ├── Excitotoxicity (glutamate release)
    ├── Calcium influx → CaMKII activation
    │
    ▼
SECONDARY INJURY CASCADES
    │
    ├── Oxidative stress (ROS generation) ──→ Nrf2/HO-1 pathway
    ├── Neuroinflammation ──→ NF-κB, NLRP3 inflammasome, HMGB1
    ├── Apoptosis ──→ Caspase cascades
    ├── Ferroptosis ──→ GPX4 pathway
    ├── Pyroptosis ──→ Gasdermin-D
    └── Autophagy dysregulation
    │
    ▼
NEURONAL AND GLIAL CELL DEATH
    │
    ├── Anterior horn motor neuron destruction → Flaccid paralysis
    ├── Spinothalamic tract damage → Loss of pain/temperature
    ├── Corticospinal tract damage → Upper motor neuron signs (late)
    └── Autonomic pathway damage → Bladder/bowel dysfunction
    │
    ▼
CLINICAL MANIFESTATION: ASAS TRIAD

Vascular Anatomy

The spinal cord receives blood supply from three longitudinal arteries. The single midline ASA (UBERON:0005431) is formed by branches from the vertebral arteries and reinforced by radiculomedullary arteries at various segmental levels. The artery of Adamkiewicz, the largest feeder, originates at T9-T12 on the left side in ~81% of individuals (PMID: 36152330). The mid-thoracic region (T4-T8) is a watershed zone particularly vulnerable to ischemia.

The left and right anterior radiculomedullary arteries show distinct distributions: 252 arteries from C2-C8 were slightly dominant on the right, while 236 arteries from T1-L2 were obviously dominant on the left, with the transition occurring at C8-T1 (PMID: 31399898).

Molecular Mechanisms

As described in a comprehensive review: "Oxidative stress is an important pathological event of ischemia/reperfusion injury. Oxidative stress can initiate multiple inflammatory and apoptotic pathways, triggering a series of destructive events such as inflammatory responses and cell death, further deteriorating the microenvironment at the injured site, and leading to neurological dysfunction" (PMID: 40630671).

Key signaling pathways:

Cellular Processes (GO Terms)

• Apoptotic process (GO:0006915)
• Inflammatory response (GO:0006954)
• Response to oxidative stress (GO:0006979)
• Response to ischemia (GO:0002931)
• Autophagy (GO:0006914)
• Cell death (GO:0008219)

Cell Types Involved (CL Terms)

Immune System Involvement

Neuroinflammation is critical to secondary injury. Anti-HMGB1 therapy "significantly improved neurological outcomes, reduced the extent of spinal cord infarction, preserved motor neuron viability, and decreased the presence of activated microglia and infiltrating neutrophils" (PMID: 40943562). Autoimmune vasculitis (Behçet's disease, SLE) represents a distinct subset.

7. Anatomical Structures Affected

Organ Level

Primary: Spinal cord (UBERON:0002240), anterior spinal artery (UBERON:0005441)

Secondary: Urinary bladder, gastrointestinal tract, skeletal muscle (atrophy), skin (pressure injuries), lungs (high cervical lesions)

Body systems: Nervous (primary), cardiovascular (underlying cause), urinary, musculoskeletal

Tissue and Cell Level

Subcellular Level

• Mitochondria (GO:0005739): Energy failure, ROS generation
• Endoplasmic reticulum (GO:0005783): ER stress
• Cell membrane: Lipid peroxidation, ion channel dysfunction
• Nucleus (GO:0005634): DNA damage, apoptotic signaling

Localization

• Thoracic spinal cord (UBERON:0003038): Most commonly affected (watershed zone)
• Cervical spinal cord (UBERON:0002726): When cervical ASA occluded — bilateral arm paresis (PMID: 10773652)
• Conus medullaris: "Snake-eye appearance" on MRI (PMID: 36998945)
• Lateralization: Typically bilateral and symmetric, but unilateral presentations occur with sulcal artery occlusion (PMID: 40104967, PMID: 30300819)

8. Temporal Development

Onset

• Typical age: Adult-onset, mean ~59 years (PMID: 11641795); pediatric cases mean 13.2 years (PMID: 28578817)
• Onset pattern: Acute to hyperacute — minutes to 48 hours to peak (PMID: 30093205)
• Typically preceded by sudden back pain

Progression

• Disease course: Monophasic (single event); chronic residual deficits; NOT relapsing-remitting
• Recovery timeline: In 9 patients followed 15–41 months: 4 walked independently, 1 with support (PMID: 30093205)

Critical Periods

• First 4.5–6 hours: Window for potential thrombolytic therapy (PMID: 22962400, PMID: 26386968)
• First 24 hours: Critical for hemodynamic augmentation and CSF drainage
• First 3–4 months: Period of most significant functional recovery (PMID: 22193225)
• Delayed SCI after TEVAR: Can occur months to years post-procedure (PMID: 38304669)

9. Inheritance and Population

Epidemiology

ASAS is rare. Spinal cord infarction accounts for ~1–2% of all strokes. ASAS represents ~49% of spinal cord ischemia cases (PMID: 25398656). Estimated incidence of all spinal cord infarction is approximately 3.1 per 100,000 person-years. After aortic surgery, SCI incidence ranges from 0–10.6% for TEVAR to 0–35% for thoracoabdominal repair (PMID: 34740806).

Inheritance

Not applicable — ASAS is an acquired vascular condition with no Mendelian inheritance pattern. Predisposing conditions (Marfan, vascular EDS) follow autosomal dominant inheritance.

Population Demographics

• Sex ratio: Male predominance (~60–67%) (PMID: 38365009)
• Age distribution: Bimodal — peak in adolescents (fibrocartilaginous embolism) and older adults (atherosclerotic/surgical causes)
• Geographic distribution: Worldwide; correlates with cardiovascular disease burden
• Ethnic predisposition: None documented; risk mirrors cardiovascular disease prevalence

10. Diagnostics

MRI (Gold Standard)

MRI findings are highly characteristic. In anterior spinal artery infarcts: "MRI findings in anterior spinal artery infarcts included pencillike hyperintensities on T2 sagittal (n = 16, 100%) and 'owl eye' appearance on T2 axial (n = 6, 37.5%) images. Diffusion restriction was noted in 8 cases and enhancement was noted in 2 cases" (PMID: 30093205).

The "snake-eye appearance" on axial MRI in conus infarction: "acute onset of conus medullaris syndrome combined with 'snake-eye appearance' should be strongly suspected as conus medullaris infarction caused by anterior spinal artery ischemia" (PMID: 36998945).

Additional Diagnostic Studies

• CT angiography of aorta: Identify dissection, aneurysm, atherosclerosis
• Digital subtraction angiography: May show ASA occlusion (PMID: 16718293)
• CSF analysis: Elevated protein without pleocytosis (distinguishes from inflammatory myelitis); exclude AQP4/MOG antibodies (PMID: 41137336)
• Electrophysiology: Absent CMAPs predict poor prognosis — "CMAP could be seen a marker of prognosis for ASAS patients, and absent CMAP might forecast the bad prognosis" (PMID: 16718293)
• ASIA Impairment Scale: Standard neurological classification (A through E)

Genetic Testing

Not applicable for ASAS itself. Relevant for underlying predisposing conditions (thrombophilia panel, connective tissue disorder genes) in young patients without clear etiology.

Differential Diagnosis

11. Outcome / Prognosis

Survival and Mortality

In the largest published series (36 patients): "the average age of the patients was 59.3 years, with a mortality of 22.2% during the hospital stay. Regarding the functional outcomes at the moment of discharge, it must be pointed out that 57.1% of the patients were wheelchair users, 25% were ambulatory, using technical aids, and 17.9% were fully ambulatory" (PMID: 11641795).

Prognostic Factors

"Prognosis is primarily determined by the severity of motor or sensory involvement, in particular, initial and nadir ASIA A/B scores which strongly correlate with poor outcome. In the majority of series, 40-60% of patients had initial ASIA A/B scores with a similar proportion remaining wheelchair dependent on follow-up" (PMID: 26154150).

Complications

Deep vein thrombosis, pulmonary embolism, urinary tract infections, pressure ulcers, chronic neuropathic pain, spasticity, pneumonia (cervical lesions), depression, neurogenic bladder (persistent in 6/7 pediatric patients — PMID: 28578817).

12. Treatment

Current Management

There is no disease-specific pharmacotherapy for ASAS. Treatment is largely supportive and empirical.

Acute phase:

Rehabilitation (cornerstone of long-term management): - Physical therapy (MAXO:0000011), occupational therapy (MAXO:0000535) - Bladder management (intermittent catheterization — MAXO:0000474) - Pain management (gabapentin, pregabalin for neuropathic pain) - Psychological support - Satisfactory functional recovery may require 3–4 months; complete independence achievable at 1 year in favorable cases (PMID: 22193225)

Experimental/Preclinical Therapeutics

Perioperative Prevention Strategies

• Intraoperative neuromonitoring (MEPs, SSEPs)
• Staged procedures for extensive aortic coverage
• MISACE before fenestrated/branched endovascular repair: SCI 9.5% vs 30% without (PMID: 41418893)
• Minimizing aortic cross-clamp time
• Multimodal spinal cord protection bundles (PMID: 34740806)

13. Prevention

Primary Prevention

• Cardiovascular risk factor modification (smoking cessation, BP control, lipid management, diabetes control)
• Atherosclerosis prevention
• Anticoagulation for thrombophilic states/atrial fibrillation

Secondary Prevention (Perioperative)

• Cerebrospinal fluid drainage protocols (PMID: 34740806)
• Blood pressure augmentation (MAP >80–90 mmHg)
• Intraoperative neuromonitoring (PMID: 32502625)
• Staged aortic repair
• MISACE (PMID: 41418893)
• Avoidance of prolonged hypotension (PMID: 12483181)

Tertiary Prevention

• DVT prophylaxis, pressure ulcer prevention, UTI prevention
• Respiratory care (high cervical lesions)
• Spasticity management
• Psychological support

14. Other Species / Natural Disease

Naturally Occurring Disease

Dogs (NCBI Taxon: 9615): Fibrocartilaginous embolism causing spinal cord infarction is well-recognized in veterinary medicine. "The disease has been found more frequently in dogs" (PMID: 7202135). Large and giant breed dogs are most commonly affected. The canine model has provided important insights into the pathogenesis of nucleus pulposus embolism.

Horses (NCBI Taxon: 9796): Spinal cord ischemia reported from fibrocartilaginous embolism or verminous arteritis.

Cats (NCBI Taxon: 9685): Rare reports of fibrocartilaginous embolism.

Pigs (NCBI Taxon: 9823): Used as experimental models due to similar vascular anatomy (PMID: 32115761).

Comparative Biology

Spinal cord vascular anatomy is conserved across mammals. The vulnerability of the ASA territory to ischemia is a shared feature due to the precarious watershed blood supply. Fibrocartilaginous embolism occurs across multiple mammalian species, suggesting a conserved pathomechanism.

15. Model Organisms

Animal Models of Spinal Cord Ischemia

Model Characteristics

Phenotype recapitulation: Rodent models reliably produce hind limb motor deficits. Histological changes include motor neuron loss, vacuolization, and pyknosis in lumbar anterior horn (PMID: 40885467). Molecular cascades mirror human pathophysiology.

Limitations: Small animal models lack the complex arterial anatomy of humans. Aortic cross-clamp models cause global ischemia rather than isolated ASA territory infarction. Recovery mechanisms may differ between species. Porcine models most closely approximate human spinal vascular anatomy.

Key Findings Summary

F1: Disease Definition and Identifiers

ASAS (MONDO:0006650) is ischemia/infarction in the distribution of the anterior spinal artery, affecting the ventral two-thirds of the spinal cord. Key identifiers include MeSH D020759, SNOMED CT 2972007, DOID 6712, and UMLS C0221069.

F2: Multiple Vascular Etiologies with Aortic Disease Predominant

Aortic pathology (atherosclerosis, dissection, surgery) accounts for 35–50% of identifiable cases. Fibrocartilaginous embolism is rare but important in young patients. 20–36% remain idiopathic.

F3: Characteristic Clinical Triad

Motor paralysis, dissociated sensory loss (pain/temperature lost, proprioception preserved), and autonomic dysfunction. Symptom onset to peak ranges from minutes to 48 hours.

F4: Poor Prognosis with Variable Recovery

In-hospital mortality ~22%. At discharge: 57% wheelchair-dependent, 25% ambulatory with aids, 18% fully ambulatory. Initial ASIA A/B scores strongly predict poor outcome.

F5: Pathognomonic MRI Features

Pencil-like T2 hyperintensity (100%), "owl eye" sign (37.5%), diffusion restriction, and cord swelling. "Snake-eye appearance" in conus infarction.

F6: Ischemia-Reperfusion Molecular Cascades

Oxidative stress, neuroinflammation (NF-κB, NLRP3, HMGB1), apoptosis, ferroptosis, and pyroptosis represent key pathophysiological mechanisms with multiple potential therapeutic targets.

Limitations and Knowledge Gaps

1. Limited epidemiological data: No population-based incidence/prevalence studies exist specifically for ASAS
2. No randomized controlled trials: All treatments based on case reports/series; Level I evidence completely lacking
3. Diagnostic delay: Initial MRI may be normal in some cases; DWI not always acquired
4. No validated biomarkers: Beyond electrophysiological markers (CMAPs), no serum/CSF biomarkers for early diagnosis
5. Translational gap: Numerous preclinical neuroprotective agents but none translated to clinical use
6. Idiopathic cases: 20–36% have no identifiable etiology
7. Sparse long-term data: Follow-up beyond 2–3 years poorly characterized
8. No human omics data: All molecular pathway data from animal models
9. Pediatric knowledge gap: Pathogenesis of childhood idiopathic SCI remains unclear (PMID: 28578817)

Proposed Follow-up Experiments / Actions

1. Multicenter prospective ASAS registry — Standardized data collection on incidence, etiology, treatment, and outcomes
2. Biomarker discovery — Proteomics/metabolomics of CSF and serum in acute ASAS (neurofilament light, GFAP, S100B)
3. Thrombolysis clinical trial — Multicenter trial of IV rt-PA for acute ASAS (after excluding dissection/hemorrhage)
4. CaMKII inhibitor translational studies — Advance tatCN19o from mouse to large animal models
5. Anti-HMGB1 therapy development — Advance from rabbit models toward clinical translation
6. Standardized emergency MRI protocol — Include mandatory DWI sequences and optimized timing
7. Genetic susceptibility studies — GWAS in idiopathic ASAS patients
8. Single-cell transcriptomics — Map cell-type-specific responses at multiple post-ischemia time points
9. Rehabilitation RCTs — Compare early intensive rehabilitation to standard care
10. Preoperative spinal vascular mapping — Non-invasive MR angiography for high-risk aortic surgery patients

Evidence Base — Key Citations

Report generated: 2026-05-05 Based on systematic analysis of 107 published studies and 6 confirmed findings Disease: Anterior Spinal Artery Syndrome (MONDO:0006650)